FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.
Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...
Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...
Hosted on MSN
Dupixent updates, access hurdles and new hope
Dupixent continues to transform treatment for atopic dermatitis and other conditions, with new FDA approvals and updated clinical guidelines boosting its role. But patients and providers still face ...
By Puyaan Singh and Kunal Das April 29 (Reuters) - Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter ...
TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported first-quarter results that exceeded expectations, supported by strong ...
Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...
Proportion of patients with complete response (UAS7=0).
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results